adipobioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Soluble VEGF R3 (sVEGFR3)ELISA
Soluble FLT-4 ELISA

Alternative name:

  • Fms Related Tyrosine Kinase
  • Tyrosine-Protein Kinase Receptor FLT4
  • Fms-Like Tyrosine Kinase
  • VEGFR-3
  • VEGFR3
  • FLT-
Receptor for VEGFC, VEGFD.

Presence of VEGF-R3 in the serum of metastatic malignant melanoma patients: Relationship with clinicobiological parameters.

The presence of metastases is a strong indicator of poor survival in many types of cancer. It has recently been shown that vascular endothelial growth factor-C (VEGF-C), and its receptor Flt-4 (VEGF-R3) are increased in a variety of tumours and may play a pivotal role in the promotion of metastasis. We previously demonstrated that high soluble VEGF-C level was correlated to high tumor burden. Objectives: This study was designed to i) detect and evaluate whether soluble VEGF-R3 play a role in metastatic malignant melanoma patients ii) to determine if they have any relationship with clinicobiological parameters, clinical response and survivals. Methods and Patients: using a sensitive enzyme-linked immunosorbent assays, VEGF-R3 was retrospectively measured in sera of 60 patients with a fully documented history of melanoma disease in comparison with 30 healthy controls. Disease free survival (DFS) and overall survival (OS) were calculated from the beginning of treatment until either the progression (DFS) or death (OS) and analyzed using the Kaplan-Meier method. Results: Pretreatment circulating VEGF-R3 was detectable in all samples from either melanoma patients or healthy donors. Furthermore, median level of sVEGF-R3 was significantly higher (p = 0.000015) in melanoma patients as compared to healthy donors. (38890 vs 30773 pg/ml respectively). No significant association was noted between sVEGF-R3 levels and gender, age or LDH level. Median serum VEGF-R3 level was significantly higher in patients with high tumor burden as compared to patients with low tumor burden (p = 0.045). The pretreatment sVEGF-R3 level was significantly different (p = 0.025) between responder (n = 27) and non-responding patients (n = 33). Lastly, the relapse-free survival was higher in the group with low sVEGF-R3 concentration compared to the high one's (14.1 vs 11,9 months) as well as for OS (14.3 Vs 12.6 months) but theses differences were not significant (ψ2 = 2,30, p = 0.12 & ψ2 = 0.74, p = 0.37 respectively). Conclusion: these results suggest that high pretreatment sVEGF-R3 level is related to bad prognosis in melanoma patients.
R. Mouawad,  et al. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 18004
Human Soluble VEGFR2 ELISA
Code No.: SK00123-02
Size: 96 T
Price: $360.00 USD
Standard Range:31-2000 pg/ml
Sensitivity:7.8 pg/ml
Sample Type: serum, EDTA plasma
Dolution Factor: 20-40
Sample requres: 25 ul
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
 
Human Soluble VEGFR3 ELISA
Code No.: SK00124-06
Size: 96 T
Price: $460.00 USD
Standard Range:187-6000 pg/ml
Sensitivity:100 pg/ml
Sample Type: serum, EDTA plasma
Dolution Factor: 20-40
Sample requres:5-10 ul
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF

 

Name
Code No.
Size
Price ($)
Soluble VEGF-R3(Human) ELISA Kit
SK00124-02
96 T
360.00
Soluble VEGF-R3(Human) ELISA Kit
96 T
460.00